• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4642359)   Today's Articles (91)   Subscriber (50473)
For: Ramirez P, DiPersio JF. Therapy options in imatinib failures. Oncologist 2008;13:424-34. [PMID: 18448557 DOI: 10.1634/theoncologist.2007-0170] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]  Open
Number Cited by Other Article(s)
51
Christoffersen T, Guren TK, Spindler KLG, Dahl O, Lønning PE, Gjertsen BT. Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. Eur J Pharmacol 2009;625:6-22. [DOI: 10.1016/j.ejphar.2009.10.009] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2009] [Revised: 09/30/2009] [Accepted: 10/08/2009] [Indexed: 12/19/2022]
52
Roche S, McMahon G, Clynes M, O’Connor R. Development of a high-performance liquid chromatographic–mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:3982-90. [DOI: 10.1016/j.jchromb.2009.10.008] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2009] [Revised: 10/04/2009] [Accepted: 10/05/2009] [Indexed: 12/27/2022]
53
Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL. Leukemia 2009;23:2242-7. [PMID: 19798092 DOI: 10.1038/leu.2009.194] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
54
E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. Blood 2009;114:4197-208. [PMID: 19734451 DOI: 10.1182/blood-2008-12-190934] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]  Open
55
Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 2009;6:352-66. [PMID: 19483740 DOI: 10.1038/nrclinonc.2009.62] [Citation(s) in RCA: 169] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
56
The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL. Leukemia 2009;23:1614-21. [PMID: 19369965 DOI: 10.1038/leu.2009.69] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
57
Martin MG, Dipersio JF, Uy GL. Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leuk Lymphoma 2009;50:14-23. [PMID: 19117213 DOI: 10.1080/10428190802517765] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
58
Okabe S, Tauchi T, Ohyashiki JH, Ohyashiki K. Mechanism of MK-0457 efficacy against BCR–ABL positive leukemia cells. Biochem Biophys Res Commun 2009;380:775-9. [DOI: 10.1016/j.bbrc.2009.01.141] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2009] [Accepted: 01/26/2009] [Indexed: 10/21/2022]
PrevPage 2 of 2 12Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA